Bone Density and Osteoporosis: Understanding Your Bone Health
Bone density, measured as bone mineral density (BMD), indicates the amount of mineral matter per square centimeter of bone. It is the primary clinical measurement used to diagnose osteoporosis and predict fracture risk. The World Health Organization established a classification system using T-scores — a comparison of your bone density to a healthy 30-year-old adult of the same sex. Understanding your T-score and risk factors is essential for taking proactive steps to maintain bone health throughout life.
WHO T-Score Classification
Normal: T-score ≥ -1.0
Osteopenia: -1.0 to -2.5
Osteoporosis: ≤ -2.5
Severe Osteoporosis: ≤ -2.5 + fracture
Each -1.0 = ~10-12% lower density
Each -1.0 = ~1.5-2x fracture risk increase
Risk Factor Scoring (FRAX-based):
Female: +0.5 | Age 50+: +(age-50)×0.04
Low weight: +0.5 | Parent fracture: +1.0
Smoking: +0.5 | Glucocorticoids: +1.0
RA: +0.5 | Alcohol 3+/day: +0.5
Sedentary: +0.3 | Low Ca/VitD: +0.3 each
10-yr fracture risk:
Low: <10% | Moderate: 10-20% | High: >20%
What Causes Bone Loss and Who Is at Risk
Bone is living tissue that constantly remodels itself through a cycle of bone resorption (old bone breakdown by osteoclasts) and bone formation (new bone created by osteoblasts). Until approximately age 30, formation exceeds resorption, and peak bone mass is achieved. After age 30, resorption gradually exceeds formation, resulting in a slow decline in bone mineral density of about 0.5-1% per year. This rate accelerates significantly during and after menopause in women.
For women, the most dramatic bone loss occurs in the first 5-7 years after menopause due to the sharp decline in estrogen, which plays a critical role in suppressing osteoclast activity and maintaining bone density. Women can lose up to 20% of their bone density during this period, which is why postmenopausal women are the highest-risk population for osteoporosis. Men also lose bone with age, but more gradually, as testosterone (which converts to estrogen in bone tissue) declines slowly rather than abruptly.
Beyond aging and hormones, several factors affect bone density. Non-modifiable factors include genetics (accounting for 60-80% of peak bone mass), sex (women have lower peak bone mass and smaller bones), ethnicity (Caucasian and Asian populations have higher rates), and family history of fractures — particularly a parental hip fracture, which roughly doubles your risk. Modifiable factors include calcium and vitamin D intake, physical activity level (especially weight-bearing exercise), smoking status (smokers lose bone faster), alcohol consumption (more than 3 drinks daily accelerates loss), body weight (underweight individuals have less bone-loading stimulus), and medications — particularly glucocorticoids like prednisone, which are among the strongest drug-related risk factors for bone loss even at low doses taken for more than 3 months.
The DEXA Scan: Gold Standard for Bone Density Measurement
Dual-energy X-ray Absorptiometry (DEXA or DXA) is the gold standard test for measuring bone mineral density. The scan is painless, non-invasive, and uses very low radiation — about one-tenth of a standard chest X-ray. It typically measures density at the hip and lumbar spine, the two sites most clinically relevant for predicting fractures. Results are reported as a T-score (comparison to a young adult reference) and a Z-score (comparison to age-matched peers). Screening is recommended for all women at age 65 and men at age 70, with earlier screening for those with risk factors such as glucocorticoid use, early menopause, low body weight, or family history of osteoporotic fractures.
Treatment decisions are based on the combination of T-score and overall fracture risk assessment. The FRAX tool, developed by the WHO, calculates 10-year probability of major osteoporotic fracture (hip, spine, forearm, or humerus) using clinical risk factors with or without DEXA results. Current guidelines typically recommend pharmacological treatment when the 10-year probability of major fracture exceeds 20% or hip fracture exceeds 3%. Available medications include bisphosphonates (alendronate, risedronate, zoledronic acid), denosumab, teriparatide, and romosozumab, each with different mechanisms and risk-benefit profiles that should be discussed with a healthcare provider.